Proficio Capital Partners LLC Purchases Shares of 58,465 Hologic, Inc. (NASDAQ:HOLX)

Proficio Capital Partners LLC purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 58,465 shares of the medical equipment provider’s stock, valued at approximately $4,215,000.

Several other large investors have also recently bought and sold shares of the stock. First Horizon Advisors Inc. raised its holdings in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the period. Brooklyn Investment Group grew its position in shares of Hologic by 14.7% during the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after purchasing an additional 145 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC grew its position in shares of Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock worth $602,000 after purchasing an additional 169 shares in the last quarter. Finally, Loomis Sayles & Co. L P grew its position in shares of Hologic by 29.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock worth $66,000 after purchasing an additional 183 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of analyst reports. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Wolfe Research assumed coverage on shares of Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Jefferies Financial Group assumed coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target on the stock. Raymond James reiterated an “outperform” rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Finally, Stephens reiterated an “overweight” rating and set a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $61.82 on Tuesday. The company has a market cap of $13.87 billion, a price-to-earnings ratio of 19.50, a PEG ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a 50 day simple moving average of $66.94 and a 200 day simple moving average of $74.51. Hologic, Inc. has a one year low of $60.34 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.